Billions for biotech: Oberland boosts biotech fund-raising past the $5B mark in a matter of weeks
Nobody appreciates nabbing a sweet late-stage investment deal more than the Oberland Capital team.
Operating in a highly competitive field, the group backed John Hood …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
